Talphera, Inc. reports news centered on its specialty pharmaceutical development business, with recurring updates on Niyad, nafamostat research, continuous renal replacement therapy and medically supervised care settings. Company announcements commonly cover financial results, corporate updates, clinical-study developments, research presentations and regulatory designations tied to the Niyad program.
Other recurring Talphera news includes financings involving common stock and pre-funded warrants, board and governance changes, investor events and business updates related to its development-stage pharmaceutical portfolio.
Talphera (Nasdaq: TLPH) reported third-quarter 2026 results and sought FDA feedback on closing enrollment in its pivotal NEPHRO CRRT study early. The proposed cutoff is December 31, 2026, even if enrollment falls below the targeted 70 patients. More than 75% are enrolled, but recruitment has slowed because fewer patients qualify. Talphera believes current enrollment provides over 80% statistical power for the primary endpoint and could support a premarket approval application; enrollment remains open and the study blinded.
Quarterly net loss narrowed to $4.018 million, or $0.05 per share, from $4.436 million, or $0.11 per share, a year earlier. Operating expenses rose to $4.136 million from $3.423 million. Cash and investments totaled $14.157 million at September 30, versus $20.381 million at December 31, 2025. Talphera raised its estimated peak CRRT sales for nafamostat to more than $200 million.
Talphera (Nasdaq: TLPH) will discuss third-quarter 2026 financial results and recent business progress on a conference call on November 12, 2026. The call and webcast begin at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time and cover the quarter ended September 30, 2026. A webcast replay will remain available on the company website for 90 days after the event.
Talphera (TLPH)/b) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, at 4:30 p.m. ET in New York, NY.The session will feature a fireside chat and 1x1 meetings with CEO Vince Angotti and Chief Medical Officer Shakil Aslam, MD. A webcast and 90-day replay will be available via Talphera’s investor website.
Talphera (Nasdaq: TLPH) reported second quarter 2026 results and a corporate update on nafamostat. The NEPHRO CRRT registrational study of lead candidate Niyad reached 75% enrollment and is expected to complete this year, with all target clinical sites now activated.
Draft 2026 KDIGO acute kidney guidelines, after public comment, cited nafamostat as an acceptable CRRT anticoagulant, a change from prior recommendations. Updated market research estimates about 200,000 U.S. CRRT procedures in 2027, a 21% increase over Talphera’s prior estimate. The company regained Nasdaq $1 bid-price compliance.
For Q2 2026, cash and investments were $17.1 million. Combined R&D and SG&A expenses were $3.9 million, up from $3.7 million a year earlier. Net loss attributable to common shareholders was $4.3 million, or $0.06 per share, versus $3.5 million, or $0.10 per share, in Q2 2025.
Talphera (Nasdaq: TLPH) will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m. ET / 1:30 p.m. PT to discuss its second quarter 2026 financial results and recent business progress. North American participants can dial 1-800-836-8184 and international participants 1-646-357-8785 using conference ID 50873. A live webcast and a 90-day replay will be available via the Upcoming Events page in the Investors section of the Talphera website.
Talphera (Nasdaq:TLPH) reported first quarter 2026 results and a clinical update. The NEPHRO CRRT nafamostat study surpassed 50% enrollment and is expected to complete in 2026. In March, Talphera closed a $4.1 million tranche tied to enrollment milestones.
As of March 31, 2026, cash and investments totaled $21.1 million. Combined R&D and SG&A expenses were $3.9 million, up from $2.9 million a year earlier. Net loss attributable to common shareholders was $2.6 million, or $0.04 per share, unchanged in dollar terms from 2025 but with a lower loss per share.
Talphera (Nasdaq: TLPH) will release Q1 2026 financial results after market close on Wednesday, May 13, 2026, followed by a live webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT.
The webcast includes a slide presentation; a replay will be available on the Talphera investor website for 90 days. Dial-in details and conference ID 24180 are provided for live participation.
Talphera (Nasdaq: TLPH) announced two abstracts accepted for presentation at AKI & CRRT 2026 (March 29–April 2, 2026) describing nafamostat as a regional anticoagulant for CRRT. One poster details the ongoing registrational NEPHRO-CRRT trial now enrolling patients; the other reports porcine PK/PD data showing >95% pre-filter removal and minimal systemic ACT effect.
The company says a target post-filter ACT of 175–225 seconds may provide extracorporeal anticoagulation while limiting systemic effects; if approved, nafamostat would be the first FDA-approved regional anticoagulant for CRRT.
Talphera (Nasdaq: TLPH) reported Q4 and full‑year 2025 results and a corporate update on March 23, 2026. Key items: 50% enrollment (35 of 70) in the NEPHRO CRRT registrational study, closing of a $4.1M financing tranche, and $20.4M cash and investments at December 31, 2025.
Q4 combined R&D and SG&A were $3.5M, net loss attributable to common shareholders was $3.8M (or $0.06 per share). 2026 cash operating expenses are guided to $17–18M. A virtual investor day was held March 23, 2026.
Talphera (Nasdaq: TLPH) will host a virtual investor and analyst event on March 23, 2026 at 11:00 AM ET to discuss Niyad for use in continuous renal replacement therapy (CRRT).
Presenters Blaithin McMahon, PhD, MBBChr, and Joao Teixeira, MD, principal investigators in the NEPHRO CRRT study, will review CRRT anticoagulation practices, nafamostat's profile, and a live Q&A will follow.